Depakote ER Shortage: What Providers and Prescribers Need to Know in 2026

The brand-name Depakote ER (divalproex sodium extended-release) supply disruption, confirmed by AbbVie as a manufacturing delay affecting 500 mg tablets, is now entering its third year. For prescribers managing patients on valproate therapy — whether for epilepsy, bipolar disorder, or migraine prophylaxis — this ongoing shortage has created clinical and logistical challenges that require a proactive approach.

This article provides a clinical overview of the current supply situation, guidance on when formulation switches are appropriate, safety considerations for the epilepsy population, and practical tools for helping patients access their medication.

Current Supply Status of Depakote ER

As of 2026, brand-name Depakote ER 500 mg remains intermittently available, with supply disruptions at the wholesaler and pharmacy level driven by manufacturing delays at AbbVie. The 250 mg strength has had slightly better availability. Generic divalproex sodium ER (250 mg and 500 mg) from multiple manufacturers remains the more consistently available option.

The shortage is not listed on the FDA Drug Shortages database at the time of this writing, which means patients may not find official confirmation of the disruption and may struggle to advocate for themselves. Prescribers should be aware that patient-reported pharmacy delays are clinically credible and consistent with manufacturer-confirmed supply issues.

Clinical Considerations: When Is a Formulation Switch Appropriate?

The appropriateness of a formulation switch depends heavily on the patient's primary indication:

Bipolar Disorder: Switching from brand Depakote ER to generic divalproex ER is generally appropriate, as the clinical relevance of minor pharmacokinetic differences is lower than in epilepsy. The primary considerations are tolerability and formulary coverage. If a generic substitution is made, monitor for changes in clinical response over the following 2–4 weeks.

Migraine Prophylaxis: Generic substitution is clinically straightforward for migraine patients. If Depakote ER is completely unavailable in any formulation, topiramate (Topamax) is the primary FDA-approved alternative.

Epilepsy: This requires the most caution. The FDA and the American Epilepsy Society recognize that formulation changes in anticonvulsants can affect seizure control for some patients, even between bioequivalent products. For patients with well-controlled epilepsy on brand-name Depakote ER, consider the following before switching:

Evaluate whether the patient has a history of breakthrough seizures on generic valproate formulations

Document "brand medically necessary" on the prescription if clinical judgment supports it

If switching to generic, check valproate levels within 2 weeks and monitor closely for seizure activity

Counsel patients on seizure precautions (driving, operating heavy machinery) during the transition period

Converting Between Valproate Formulations: Dose Equivalence

Providers must understand the pharmacokinetic differences between valproate formulations before making any switch:

Depakote ER (extended-release) to Depakote DR (delayed-release): When converting from Depakote ER to DR, reduce the total daily dose by approximately 8–20% to account for higher bioavailability of the DR formulation. Dosing frequency also changes from once daily (ER) to two to three times daily (DR).

Depakote DR to Depakote ER: The reverse conversion requires a dose increase of 8–20%. Trough plasma concentrations for Depakote ER are, on average, equivalent to Depakote DR, but individual variability exists.

Divalproex sodium, valproate sodium, valproic acid: These products are not interchangeable on a 1:1 basis and cannot be freely substituted. Dose adjustment and monitoring are required with any switch.

Target therapeutic serum range: 50–100 mcg/mL for epilepsy. For bipolar mania, a trough between 85–125 mcg/mL is used in clinical trials. Monitor levels within 2 weeks of any formulation change.

Key Safety Considerations for Valproate Prescribers

When managing patients on divalproex sodium, particularly during transitions, providers should keep the following in mind:

Hepatotoxicity (Black Box Warning): Perform baseline LFTs before starting or resuming valproate, and repeat at frequent intervals during the first 6 months. Risk is highest in children under 2 years and patients with mitochondrial disorders.

Fetal risk (Black Box Warning): Valproate is one of the most teratogenic medications in common use. Neural tube defects, craniofacial abnormalities, and decreased IQ have been documented. Do not prescribe for migraine in women of childbearing potential who are not using effective contraception. Document risk discussion in the chart.

Pancreatitis (Black Box Warning): Warn patients about abdominal pain, nausea, and vomiting as potential symptoms. Discontinue if pancreatitis is confirmed.

Drug interactions: Carbapenems (meropenem, ertapenem, imipenem) dramatically reduce valproate levels — avoid co-administration. Valproate significantly increases lamotrigine levels — halve the lamotrigine dose when adding valproate. Fosphenytoin and topiramate co-administration increase hyperammonemia risk.

How to Help Patients Find Depakote ER in Stock

Prescribers play a key role in helping patients navigate shortages. Practical steps include:

E-prescribe directly to a pharmacy that has confirmed stock, or ask your medical assistant to call ahead

Write "brand medically necessary" on prescriptions for seizure patients with documented brand-specific sensitivity

Recommend patients use medfinder — a service that calls pharmacies to check real-time medication availability so patients do not have to

Issue bridge prescriptions when patients are at risk of running out — partial fills using two 250 mg tablets can be a practical short-term solution

For more tools to support your patients, visit medfinder for providers.

The Bottom Line for Providers

The Depakote ER supply issue is a clinically significant problem for a specific subset of patients — particularly those with well-controlled epilepsy on brand-name valproate. Proactive patient communication, careful formulation conversion protocols, and practical tools like medfinder can significantly reduce the clinical risk and patient distress caused by this ongoing shortage.